FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Global Cannabis Applications Corp. (the "Issuer" or "GCAC")

Trading Symbol: **APP**

Number of Outstanding Listed Securities: <u>178,075,424</u> (as at May 5, 2021)

Date: May 6, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a global leader in designing, developing, SaaS licensing and acquiring innovative data technologies for the medical cannabis industry. Its Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, the Issuers is focused on generating revenue from SaaS licensing its technology and acquiring high quality cannabis datasets that improve patient outcomes and to become the world's largest cannabis efficacy data provider.

During the month of April 2021, the Issuer actively continued general and corporate operations.

Global Outbreak of COVID-19 Disclosure: The actual and threatened spread of the virus globally has had a material adverse effect on the regional economies in which the Issuer operates and could continue to result in negative impacts on the stock market, including trading prices of the Issuer's shares and the ability to raise capital, and could impact the Issuer's operations.

2. Provide a general overview and discussion of the activities of management.

During the month of April 2021, management continued to support and control the Issuer's business activities and develop the Issuer's business with a focus on creating broader awareness of the Issuer and continued development of product line.

On April 8, 2021, the Issuer announced by way of news release that has initiated a comprehensive marketing initiative designed to greatly amplify the message and mission of the organization to its key audiences – medical cannabis growers, consumers, resellers, and investors.

The Issuer is executing its marketing plan to bring its Citizen Green cannabis compliance technologies to more cannabis cultivators and to increase investor awareness in the US, Canada and Europe. Building-on its recent capital markets success in attracting \$3 million of new investment, The Issuer's latest investor outreach initiatives also seek to expand its investor base in China.

This multi-channel communications strategy involves marketing, promotion, thought leadership development, and strategic social media activation of several upcoming high-profile opportunities:

- Securing a dedicated public relations agency to facilitate outreach and earned media interviews and placements
- Engaging through ongoing television, radio, and podcast interviews featuring the Issuer's CEO Brad Moore, which includes Fox News, Bloomberg, New to the Street and more
- Speaking engagements at high-profile events also featuring Brad Moore, expanding the reach and engagement of the Issuer to a global level

Upcoming events include:

- 4/14: WallStreet Research Virtual Webinar and Q&A Series
- 4/15: Global Chinese Financial Forum (GCFF) Virtual Conference 2021
- 6/22-23: Cannabis Business Europe 2021, Frankfurt, Germany

On April 13, 2021, the Issuer announced by way of news release a definitive three-year software licensing agreement with Herb Industries Ltd. ("Herb"), a Malta based medical cannabis cultivator. Grams cultivated are forecast as 44M in 2022 and 66M in 2023.

The Issuer is licensing its Citizen Green Efixii platform as part of Herb's 'technology farm' for use in its cannabis compliance and consumer transparency. Herb's advanced-growth-method handles all production lifecycles from genetics, cannabis nursery, onsite ISO laboratory and extraction. Licensed by the Maltese government, Herb's 12,000 SQM facility's manufacturing lines will export to other EU members' markets for pharmaceutical, solids, semi solids, liquids, flowers, cosmetics and edibles.

The Issuer's Software-as-a-Service ("SaaS") license model meets the needs of cultivators as they scale. Cannabis lifecycle steps are represented by the Issuer's Efixii QR-code which can be scanned by customs officials, regulators, medical professionals and consumers alike to ensure that products are what they claim to be. The Issuer charges a one-time configuration fee of \$12,500 (USD), \$50 per registered employee per month for KYC/AML, an export fee of \$75 per cannabis batch and a consumer Efficacy-QR-code fee of \$75 per retail product; in total, these fees generate CDN\$.20/gram with a further potential yield of CDN\$.18/gram in future data sales.

The European cannabis market is the largest in the world, with a forecast CAGR of 67.4% set to value the market at €3.2 billion by 2025 [1]. The growth of the EU market since 2019 is attributed to consumer demand for CBD and the upgrading of regulations for medical cannabis. Key to meeting those regulations and building consumer confidence will be Herb's use of the Efixii compliance platform. Efixii enables growers' staff to record all events for cannabis cultivations, including mother plant, laboratory tests, shipment, processing and customs.

All of Efixii's cannabis data is the intellectual property ("IP") of the Issuer. This IP creates an inherent difficulty in replicating or competing with the Issuers's medical cannabis datasets. The Issuer defined their protocols in a provisional US patent application, 'System of Process and Tracking Cannabis Products and Associated Method Using Blockchain' filed with the USPTO on Dec. 17, 2020.

[11] https://www.canadianpackaging.com/general/legal-cannabis-market-in-europe-set-to-be-worth-e3-2-billion-by-2025-168895/

On April 20, 2021, the Issuer announced by way of news release that it has launched a Uniswap token^[1] as part of a digital marketing campaign aimed at the one million decentralized finance user community 'DeFi'^[2].

The Issuer believes that the Uniswap community is an excellent target audience as this key demographic are consumers that have disposable income, are under 34 years old and increasingly drawn to the use of cannabis products^[3]. This multi-year marketing campaign aims to raise awareness of its Citizen Green products and its Efixii 'QR codes' by launching a Uniswap token on the Ethereum blockchain with the Issuer's name, logo and website visible to all of the Uniswap community.

The Issuer is publicly traded with audited financials and makes accurate revenue disclosures. The Issuer's Uniswap-inclusion marketing initiative is to commit to a marketing-spend of 1% of its quarterly sales revenue buying GCAC tokens on Uniswap every 3 months. Each Uniswap token-buy should lead to greater awareness of the Issuer's products and drive potential new cannabis consumers to look for Efixii 'QR codes' on the products that they are purchasing on-line.

Mega-cap companies like Tesla (TSLA) are diversifying their balance sheets by adding the Bitcoin cryptocurrency^[4]. The Issuer is now adding an Ether cryptocurrency based "alternative asset" to its balance sheet by buying the Issuer's marketing tokens on Uniswap with 1% of its revenues. The Issuer represents the next generation of companies embracing alternative assets and continues to innovate and seek ways to expand awareness of the benefits of cannabis efficacy and product transparency.

The Uniswap GCAC marketing token is built and operated by Abbey Technology "Abbey" and this latest marketing token has a unique set of features including:

- The Issuer's commitment to purchase GCAC tokens on Uniswap with 1% of its quarterly revenues
- Preventing the smart contract from creating any new GCAC marketing tokens
- Giving advance-notice disclosure of the 'intent to redeem' any Abbey Uniswap liquidity-pool
- Giving advance-notice disclosure of the 'intent to sell' any Issuer "alternative asset" tokens

[1] https://info.uniswap.org/pair/0xf22645743415d8c06d78c8a4f0ea214041b4544f

https://medium.com/metamask/metamask-exceeds-1-million-monthly-active-users-9da72a1e915d

- [3] https://www.warc.com/newsandopinion/news/40_of_us_consumers_would_try_out_cbd_products/41878
- [4] https://apnews.com/article/tesla-buys-billion-bitcoin-061817c6795e75d1c3c9e9d6cfc4a911

The above noted news releases can be viewed under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer has launched a Uniswap token as part of a digital marketing campaign aimed at the one million decentralized finance user community 'DeFi'.

See Item #2 for further details

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report during the month of April 2021.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered into a definitive three-year software licensing agreement with Herb Industries Ltd. ("Herb"), a Malta based medical cannabis cultivator.

The licensing agreement was negotiated by arm's length negotiations and is not considered to be a related party transaction.

See Item #2 for further details

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report during the month of April 2021.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report during the month of April 2021.

8. Describe the acquisition of new customers or loss of customers.

None to report during the month of April 2021.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer has initiated a comprehensive marketing initiative designed to greatly amplify the message and mission of the organization to its key audiences – medical cannabis growers, consumers, resellers, and investors.

See Item #2 for further details.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of April 2021.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report during the month of April 2021.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of April 2021.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report during the month of April 2021.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	160,000	Common Shares issued pursuant to	\$13,600; general working capital
		the exercise of common share	
		purchase warrants at \$0.085	
Common Shares	610,500	Common Shares issued pursuant to	\$82,417.50; general working capital
		the exercise of common share	
		purchase warrants at \$0.135	

Common Shares	-13,636,363	Return to treasury for the cancellation of common shares guaranteeing repayment of a loan owed to the	N/A
		Issuer. (2)	

- (1) State aggregate proceeds and intended allocation of proceeds
- (2) The repayment of a loan in the amount of \$4,927,075 owing to the Issuer by the borrower was guaranteed by a guarantor. The loan was made pursuant to a loan agreement dated April 6, 2018 and secured by a guarantor with 13,636,363 shares of the Issuer (the "Secured Shares"). Following the completion of the enforcement action as disclosed in the Issuer's news release dated March 11, 2021, the Secured Shares were returned to the Issuer's treasury for cancellation..
- 15. Provide details of any loans to or by Related Persons.

None to report during the month of April 2021.

16. Provide details of any changes in directors, officers or committee members.

None to report during the month of April 2021.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Form 2A - Listing Statement, dated October 16, 2014 (the "Listing Statement"), under the heading "Risk Factors", as well as in the Issuer's Management Discussion and Analysis dated March 1, 2021 (the "MD&A") under the heading "Financial Instruments and Risk Management". The Listing Statement and the MD&A can be viewed under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

Certificate of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 6, 2021

Bradley Moore		
Name of Director or Senior Officer		
/s/ Bradley Moore		
Signature		
•		
Chief Executive Officer		
Official Capacity		

Issuer Details Name of Issuer Global Cannabis Applications Corp.	For Month End April 2021	Date of Report YYYY/MM/DD 2021/05/06
Issuer Address PO Box 43, Suite 830 1100 Melville Street Vancouver, BC V6E 4A6	Issuer Fax No. Not applicable	Issuer Telephone No. 1 (800) 409-5679
Contact Name Bradley Moore	Contact Position Chief Executive Officer	Contact Telephone No. (855) 269-9554
Contact Email Address info@cannappscorp.com	Web Site Address https://cannappscorp.com/	